United Therapeutics Corporation income statement & cash flow
In the fiscal year ended Dec 31, 2025, United Therapeutics Corporation reported net income of $1.33B on revenue of $3.18B. Operating cash flow was $1.56B and capital expenditures were $520.50M, leaving $1.04B of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.60B | $1.73B | $1.63B | $1.45B | $1.48B | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B |
| Gross profit | — | — | — | $1.33B | $1.38B | $1.56B | $1.78B | $2.07B | $2.57B | $2.80B |
| Operating income | $1.06B | $814.90M | $805.40M | −$187.60M | $593.60M | $555.90M | $979.70M | $1.18B | $1.38B | $1.49B |
| Net income | $713.70M | $417.90M | $589.20M | −$104.50M | $514.80M | $475.80M | $727.30M | $984.80M | $1.20B | $1.33B |
| Diluted EPS | $15.25 | $9.31 | $13.39 | −$2.39 | $11.54 | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| Operating cash flow | $643.60M | $474.20M | $778.40M | −$206.60M | $755.70M | $598.20M | $802.50M | $978.00M | $1.33B | $1.56B |
| Capital expenditures | $38.00M | $86.30M | $184.40M | $83.70M | $59.30M | $120.80M | $138.80M | $230.40M | $246.50M | $520.50M |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2020 | 10-K 2020 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | 87.9% | 46.9% | 41.9% |
| Dec 2024 | 89.2% | 47.9% | 41.5% |
| Dec 2023 | 88.9% | 50.9% | 42.3% |
| Dec 2022 | 92.2% | 50.6% | 37.6% |
| Dec 2021 | 92.7% | 33.0% | 28.2% |
Source: SEC EDGAR XBRL company facts for CIK 1082554 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.